嵌合抗原受体细胞疗法在皮肤T细胞淋巴瘤的应用

Chimeric antigen receptor cell therapy in cutaneous T-cell lymphoma

皮肤T细胞淋巴瘤(CTCL)是T细胞来源的一组异质性恶性肿瘤,疾病晚期患者尚无有效的治疗手段。嵌合抗原受体细胞疗法中使用带有识别肿瘤抗原的受体免疫细胞,此类细胞同时具有肿瘤细胞靶向性和杀伤能力,在肿瘤免疫治疗方面具有应用前景。文章就嵌合抗原受体细胞疗法在CTCL中的研究进展进行综述。

Cutaneous T cell lymphomas(CTCL)are one heterogeneous group of malignancies derived from T cell.There is no effective treatment for terminal patients.Chimeric antigen receptor(CAR)immunotherapy by using immune cells can express tumor antigen-specific receptors,target tumor cells and achieve killing ability.CAR immunotherapy has shown a meaningful application prospect in tumor immunotherapy.The progress on research of CAR immunotherapy in CTCL was reviewed in this paper.